Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 10/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14642749 | 0.85 | ADORA2B (0.45) | ATAD2HPGDADORA2BCYP3A4ADORA2A | |
| SCHEMBL13765787 | 0.80 | KDM4E (0.44) | ADORA2BRAB9AL3MBTL1CYP1A2 | |
| SCHEMBL16938290 | 0.79 | HPGD (0.51) | HPGDADORA2BCYP3A4ADORA2ACYP2D6 | |
| SCHEMBL10068141 | 0.78 | HPGD (0.70) | ATAD2HPGDADORA2BADORA2AABL1 | |
| SCHEMBL13765794 | 0.78 | ALDH1A1 (0.46) | ABL1RAB9A | |
| SCHEMBL23089548 | 0.76 | HPGD (0.51) | HPGDADORA2BCYP3A4ADORA2ACYP2D6 | |
| SCHEMBL22529508 | 0.76 | HPGD (0.51) | HPGDADORA2BCYP3A4ADORA2ACYP2D6 | |
| SCHEMBL17194984 | 0.74 | ATAD2 (0.49) | ATAD2HPGDADORA2AABL1RAB9A | |
| SCHEMBL77715 | 0.72 | ATAD2 (0.89) | ATAD2HPGDRAB9A | |
| SCHEMBL15274645 | 0.72 | ABL1 (0.47) | ATAD2HPGDABL1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461167-B2 | Acetylenic heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176781-A1 | Acetylenic Heteroaryl Compounds | NAT1, AADAC, ACACA | ATAD2 1370/4885HPGD 551/4885ADORA2B 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.